Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.

Avalere Health, Health Economics and Outcomes Services, 1350 Connecticut Ave NW, Washington, DC 20036, USA.
The American journal of managed care (Impact Factor: 2.17). 05/2011; 17 Suppl 5 Developing:SP38-44. DOI: 10.1200/JOP.2011.000316
Source: PubMed

ABSTRACT To calculate the abandonment rate of oral oncolytic medications and identify factors that may affect likelihood of abandonment.
Cross-sectional cohort study using administrative claims data.
We analyzed a nationally representative pharmacy claims database and identified 10,508 patients with Medicare and commercial insurance for whom oral oncolytic therapy was initiated between 2007 and 2009. We calculated the abandonment rate for the initial claim, in which abandonment was defined as reversal of an adjudicated pharmacy claim without a subsequent paid claim for any oncolytic (oral or intravenous) within the ensuing 90 days. We assessed likelihood of abandonment using bivariate and multivariate logistic regression analyses including patient demographics, plan type, drug type, cost sharing, and concurrent prescription activity.
The abandonment rate of newly initiated oral oncolytics was 10.0%. Unadjusted bivariate analyses found that high cost sharing, increased prescription activity, lower income, and Medicare coverage were associated with a higher abandonment rate (P <.05). In the logistic regression model, claims with cost sharing greater than $500 were 4 times more likely to be abandoned than claims with cost sharing of $100 or less (odds ratio [OR], 4.46; P <.001). Patients with 5 or more prescription claims processed within in the previous month had 50% higher likelihood of abandonment than patients with no other prescription activity (OR, 1.50; P <.001).
Abandonment of newly prescribed oral oncolytic therapy is not uncommon, and the likelihood increases for patients enrolled in plans with pharmacy benefit designs that require high cost sharing. Increased concurrent prescription activity was also associated with a higher abandonment rate. These factors should be taken into account when considering likely adherence to cancer therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To review in databases the relevant literature of adherence to chemotherapy and radiotherapy for cancer; which bring high biological, psychological, social and cultural costs and have been related to lower adherence rates. Method: A search in different databases was performed to identify relevant articles related to the key words. Results: A significant percentage of patients do not adhere to cancer treatments and the consequences of not doing it can unleash in a major risk of death or disease progression, then it is essential to approach this topic and take into account different variables of biological, psychological and social impact on the behavior of adherence or not adherence to the treatments; including the side effects, motivation, decision-making ability, emotional condition, autonomy and life philosophy of each patient. This research contributes to the health staff have more elements to approach this problem and so his interventions are more effective being able to increase the patient´s adherence. Conclusions: Adherence is a multifactorial and multi-determined construct, which has been extensively studied in non cancer treatments (e.g. AIDS) and there is few investigation that supports the efficacy of the psychological interventions to approach not adherence and to promote the adherence to cancer treatments.
    01/2012; 8(2-3). DOI:10.5209/rev_PSIC.2011.v8.n2-3.37890
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral anticancer drugs (OADs) allow treating a growing range of cancers. Despite their convenience, their acceptance by healthcare professionals and patients may be affected by medical, economical and organizational factors. The way the healthcare payment system (HPS) reimburses OADs or finances hospital activities may impact patients' access to such drugs. We discuss how the HPS in France and USA may generate disincentives to the use of OADs in certain circumstances.
    BMC Health Services Research 06/2014; 14(1):274. DOI:10.1186/1472-6963-14-274 · 1.66 Impact Factor
  • JAMA Internal Medicine 09/2014; 174(11). DOI:10.1001/jamainternmed.2014.4878 · 13.25 Impact Factor


Available from

Similar Publications